Definitive Healthcare (NASDAQ:DH) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Definitive Healthcare (NASDAQ:DH) from a hold rating to a buy rating in a research report report published on Sunday morning.

Other analysts have also recently issued reports about the stock. Zacks Research upgraded shares of Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 28th. Barclays decreased their price target on shares of Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating on the stock in a report on Monday, March 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Definitive Healthcare in a research report on Wednesday, June 3rd. Bank of America reissued an “underperform” rating and set a $0.70 price objective on shares of Definitive Healthcare in a research note on Monday, June 29th. Finally, Robert W. Baird set a $1.10 target price on Definitive Healthcare in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have issued a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $2.47.

Definitive Healthcare Stock Performance

Shares of DH opened at $0.68 on Friday. Definitive Healthcare has a twelve month low of $0.62 and a twelve month high of $4.70. The stock has a market cap of $72.07 million, a PE ratio of -0.42, a P/E/G ratio of 11.02 and a beta of 1.33. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.81. The business’s 50-day moving average price is $0.81 and its 200-day moving average price is $1.24.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $55.93 million during the quarter, compared to analyst estimates of $55.02 million. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. On average, equities analysts forecast that Definitive Healthcare will post 0.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Definitive Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of DH. Raymond James Financial Inc. bought a new position in shares of Definitive Healthcare in the 2nd quarter worth $32,000. State of Alaska Department of Revenue lifted its holdings in shares of Definitive Healthcare by 109.3% during the 4th quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock worth $32,000 after acquiring an additional 5,970 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in Definitive Healthcare in the fourth quarter worth $35,000. Bayesian Capital Management LP purchased a new position in Definitive Healthcare in the second quarter worth $55,000. Finally, Prelude Capital Management LLC purchased a new position in Definitive Healthcare in the third quarter worth $64,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.